Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#203 of 388

Patrick R. Trucchio

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2021No new ratings since Jul 2025

Analyst rating accuracy & track record

Patrick R. Trucchio is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 158 of their stock calls across 16 companies. Their picks beat their sector 35% of the time over the next 12 months, and their price targets were reached 8% of the time within a year.

Win % vs sector
35%
PT Hit % (12mo)
8%
Avg sector-excess
−6.8%
Scored calls
158
Tickers
16
Tier
Established

Track record

Quantellect has scored 158 of Patrick R. Trucchio's stock calls across 16 companies, dating back to 2021. Their rated stocks beat their own sector 35% of the time over the next 12 months. On a typical call, a Trucchio pick returned −6.8% more than its sector over the following year.

Of the scored calls, 158 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
CMPSCompass Pathways Plc
Buy$45.00Jul 2025+219.2%Miss
ALTAltimmune Inc
Buy$12.00Jun 2025−44.8%Miss
SGMOSangamo Therapeutics Inc
Buy$10.00Jun 2025−103.3%Miss
SLNSilence Therapeutics PLC
Buy$75.00Jun 2025+24.2%Miss
IMCRImmunocore Holdings Ltd
Buy$100.00Jun 2025−35.5%Miss
ONCYOncolytics Biotech Inc
Buy$5.00May 2025+81.1%Miss
DTILPrecision BioSciences Inc
Buy$60.00May 2025+38.6%Miss
ARWRArrowhead Pharmaceuticals Inc
Buy$80.00May 2025+390.0%Hit
ATAIATAI Life Sciences BV
Buy$10.00May 2025+100.3%Miss
CMPSCompass Pathways Plc
Buy$45.00May 2025+127.7%Miss
VYGRVoyager Therapeutics Inc
Buy$30.00Apr 2025+16.3%Miss
HRMYHarmony Biosciences Holdings
Buy$70.00Apr 2025−11.9%Miss
SGMOSangamo Therapeutics Inc
Buy$10.00Apr 2025−70.8%Miss
BEAMBeam Therapeutics Inc
Buy$80.00Apr 2025+56.2%Miss
ALTAltimmune Inc
Buy$12.00Apr 2025−31.5%Miss
MISTMilestone Pharmaceuticals Inc
Buy$10.00Apr 2025+58.9%Miss
MISTMilestone Pharmaceuticals Inc
Buy$25.00Mar 2025+26.0%Miss
DTILPrecision BioSciences Inc
Buy$60.00Mar 2025+13.4%Miss
DTILPrecision BioSciences Inc
Buy$60.00Mar 2025+23.9%Miss
ATAIATAI Life Sciences BV
Buy$10.00Mar 2025+159.1%Miss
GOSSGossamer Bio Inc
Buy$10.00Mar 2025−70.0%Miss
ALTAltimmune Inc
Buy$12.00Mar 2025−43.0%Miss
MISTMilestone Pharmaceuticals Inc
Buy$25.00Mar 2025−28.9%Miss
VYGRVoyager Therapeutics Inc
Buy$30.00Mar 2025+9.2%Miss
IMCRImmunocore Holdings Ltd
Buy$100.00Mar 2025+3.6%Miss
ONCYOncolytics Biotech Inc
Buy$5.00Mar 2025+59.8%Miss
BEAMBeam Therapeutics Inc
Buy$80.00Mar 2025−8.0%Miss
SLNSilence Therapeutics PLC
Buy$75.00Mar 2025+31.3%Miss
IMCRImmunocore Holdings Ltd
Buy$100.00Mar 2025−1.3%Miss
CMPSCompass Pathways Plc
Buy$45.00Mar 2025+67.7%Miss
ALTAltimmune Inc
Buy$12.00Mar 2025−37.8%Miss
VYGRVoyager Therapeutics Inc
Buy$30.00Mar 2025−4.9%Miss
MISTMilestone Pharmaceuticals Inc
Buy$25.00Feb 2025−3.0%Miss
VIRVir Biotechnology Inc
Buy$110.00Feb 2025+10.1%Miss
BEAMBeam Therapeutics Inc
Buy$80.00Feb 2025+6.5%Miss
IMCRImmunocore Holdings Ltd
Buy$100.00Feb 2025+5.3%Miss
HRMYHarmony Biosciences Holdings
Buy$70.00Feb 2025−25.1%Miss
DTILPrecision BioSciences Inc
Buy$60.00Feb 2025−42.1%Miss
CMPSCompass Pathways Plc
Buy$45.00Feb 2025+16.3%Miss
ATAIATAI Life Sciences BV
Buy$10.00Feb 2025+44.4%Miss
ALTAltimmune Inc
Buy$12.00Feb 2025−35.9%Miss
ONCYOncolytics Biotech Inc
Buy$5.00Feb 2025+15.8%Miss
SLNSilence Therapeutics PLC
Buy$75.00Feb 2025−20.4%Miss
BEAMBeam Therapeutics Inc
Buy$80.00Feb 2025+1.7%Miss
VIRVir Biotechnology Inc
Buy$110.00Jan 2025−30.2%Miss
GOSSGossamer Bio Inc
Buy$10.00Jan 2025+122.2%Miss
ATAIATAI Life Sciences BV
Buy$10.00Jan 2025+133.8%Miss
SLNSilence Therapeutics PLC
Buy$75.00Jan 2025−11.8%Miss
ATAIATAI Life Sciences BV
Buy$10.00Jan 2025+150.2%Miss
VYGRVoyager Therapeutics Inc
Buy$30.00Jan 2025−37.6%Miss
Go to

Patrick R. Trucchio: analyst track record FAQ

Is Patrick R. Trucchio a good stock analyst?

Yes, by track record. Patrick R. Trucchio ranks number 203 of 388 of the analysts Quantellect scores, with a Q Score of 30 out of 100. Past results do not guarantee future ones.

What is Patrick R. Trucchio's win rate?

Patrick R. Trucchio's win rate is 35%. Across 158 scored calls, their rated stocks beat their sector 35% of the time over the next 12 months. On a typical call they returned −6.8% more than the sector.

What stocks and sectors does Patrick R. Trucchio cover?

Patrick R. Trucchio covers 16 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Patrick R. Trucchio's price targets accurate?

Patrick R. Trucchio's price targets are reached within 12 months 8% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Patrick R. Trucchio's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Patrick R. Trucchio rank among Wall Street analysts?

Patrick R. Trucchio ranks number 203 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.